Metabolic
Tirzepatide 10mg
10mg vial
In stock
Current batch · Released 2026.04.12
Purity≥98% by HPLC
FormulaC225H348N48O68
Mechanism
Tirzepatide is a dual-agonist research peptide targeting both GLP-1 and GIP receptors. 10mg vial provides extended research duration. Third-party COA available with batch 2.
Research applications
Dual GLP-1 / GIP agonist for metabolic research.
References
- 1.Independent analytical results are summarized on the downloadable Certificate of Analysis.
- 2.Refer to primary literature for mechanism of action and pharmacokinetic data.
- 3.ClinicalTrials.gov — search compound name for registered studies.
- 4.PubMed — peer-reviewed publications indexed under compound name and CAS number.
Related compounds
Retatrutide 10mg
10mg vial
In stockVerified
Triple-receptor agonist of GLP-1, GIP, and glucagon pathways. Studied for metabolic research.
$120CADView compound →
Tesamorelin 10mg
10mg vial
Growth hormone-releasing factor analog for visceral fat research.
$120CADView compound →
Research use only. This product is intended for laboratory research purposes only. Not for human consumption. Not a drug, food supplement, or cosmetic. Not evaluated by Health Canada or the FDA for therapeutic use.
$80CAD